Bio-inspired drug delivery that goes where conventional therapies can't
Navicyte's T3MP platform mimics T lymphocyte trafficking to actively deliver drugs into the lymph node and tumor microenvironment, sites critical to oncology, autoimmune, and infectious disease, but which exhibit poor therapeutic indices for conventional therapies.
How it works: T3MPs use a proprietary bio-inspired mechanism to actively home to lymphoid tissue and tumors via the same natural pathway used by T cells, achieving targeted drug concentration at the disease site rather than relying on passive accumulation. The platform is payload-agnostic, with tunable release kinetics from weeks to months.
Lead asset Naviplatin: Preclinical data show >700% increase in lymph node drug accumulation, ~3x reduction in kidney accumulation, >500-fold therapeutic index expansion, and effective tumor control at 1/6 the standard dose.
Ideal entry point Payload Pilot Study: Navicyte formulates a partner's compound in T3MP and runs a focused, defined-scope study delivering a head-to-head comparison of free drug vs. T3MP-loaded. Outputs include: encapsulation efficiency & stability data; in vitro and in vivo biodistribution; lymph node or tumor uptake kinetics; PK/PD modeling with therapeutic index measurement; and safety profiling (toxicology, immunogenicity, cytokine profiles). Upon meeting pre-defined POC criteria, Navicyte provides a strategic IP plan, co-development roadmap, and regulatory pathway mapping leveraging existing CDMO/CRO partnerships.
Stage & Credentials: Pre-IND, FDA 505(b)(2), $1.5M+ non-dilutive funding, PCT patent filed 2021, Manufacturing partnership with Micropore Technologies active.
Seeking: Pharma/biotech partners with toxicity-limited or stalled assets, or interested overhauling PK profiles. T3MP reformulation can unlock new IP, extend exclusivity, and revive stalled programs.
About Navicyte Biotechnologies LLC
Navicyte Biotechnologies LLC has developed a proprietary targeted drug delivery platform designed to mimic natural immune cell trafficking. By functioning as a Trojan Horse, the technology delivers therapeutics directly to lymph nodes and immune-relevant tissues, allowing for precision targeting and enhanced drug efficacy. The platform is engineered to be compatible with a broad range of payloads, including oncology drugs, vaccines, immunotherapies, and nucleic acids. It offers tunable pharmacokinetics, allowing for drug release profiles ranging from hours to weeks, and is designed to be FDA and GMP-compatible with existing manufacturing pipelines.
This delivery technology is significant for developers looking to expand the therapeutic index of drugs, with preclinical models demonstrating up to a 500-fold improvement in efficacy and an 85% reduction in the required drug dose. The company focuses on addressing critical challenges in oncology, such as reducing the toxicity of chemotherapies, as well as improving treatments for HIV, tuberculosis, and vaccines. By facilitating precise access to lymphoid reservoirs and supporting in situ manufacturing, Navicyte aims to de-risk Phase I clinical trials and rescue shelved compounds. The team offers R&D resources to partners, including NIH investigators and pharmaceutical innovators, to evaluate therapeutic payloads for further translational development.
delivered to your inbox.